Thorney Technologies Ltd posted a $16.4 million net loss for FY2026, deepening from last year, as it continued to simplify its portfolio and execute a substantial share buyback program.
- Net loss widens to $16.4 million
- Net tangible asset backing falls to 21.5 cents per share
- Portfolio narrowed to higher-conviction technology investments
- 17 million shares bought back at average 10.95 cents
- Investment Management Agreement extended to December 2030
Substantial Loss Reflects Volatile Investment Landscape
Thorney Technologies Ltd (ASX:TEK) posted a net loss after tax of $16.41 million for the year ended 30 June 2026, a sharp deterioration from the $4.66 million loss recorded in FY2025. The company’s net tangible asset (NTA) backing per share declined to 21.5 cents, down from 25.4 cents the prior year, underscoring ongoing valuation pressures across its technology-focused portfolio.
The loss was driven largely by a $7.87 million unrealised decline in fair value of investments and a $18.9 million net realised loss on investment disposals. Despite these headwinds, the company maintained a disciplined approach to capital preservation and portfolio management amid a dynamic global equity environment marked by rapid technological shifts and geopolitical uncertainty.
Focused Portfolio Strategy and Capital Liberation
TEK continued its strategy of portfolio simplification during FY2026, reducing the number of holdings to concentrate on higher-conviction investments. This approach aims to enhance capital allocation effectiveness and deepen engagement with investee companies. The company generated $8.8 million in cash inflows from the sale of trading and long-term investments, more than doubling the prior year’s $3.9 million.
Among the top contributors to performance were Vitrafy Life Sciences, Dug Technologies, QuickFee, Mosh, and Calix Ltd. Conversely, investments in Nexdius, Credit Clear Limited, Yojee, Daisee, and Worthy underperformed, reflecting the inherent volatility in technology and innovation sectors.
As at 30 June 2026, TEK’s five largest listed holdings; Imricor Medical Systems, Clarity Pharmaceuticals, Credit Clear, DUG Technology, and Doctor Care Anywhere; accounted for approximately 21% of total assets. The company also became a substantial holder in Mach7 Technologies during the year, while ceasing substantial holdings in Pentanet and Terragen Holdings.
Share Buyback and Capital Management Initiatives
To address the persistent discount between TEK’s share price and its NTA, the company continued its on-market share buyback program, acquiring 17 million shares at an average price of 10.95 cents, costing $1.86 million. This represents a tactical deployment of capital intended to enhance shareholder value by repurchasing stock at significant discounts.
The Board reiterated that managing this discount remains a key priority. In February 2026, the Investment Manager’s contract was extended for seven years to December 2030, reflecting confidence in the existing management framework. However, an internal review of investment performance and the ongoing discount is underway, overseen by a Board subcommittee.
Governance and Risk Oversight
TEK’s governance framework remains robust, with a Board comprising experienced directors including Chairman Alex Waislitz OAM and non-executive members Jeremy Leibler, Alan Fisher, and Martin Casey. The company’s risk management focuses on investment and operational risks, including market volatility, credit exposures, and regulatory compliance.
The company holds a diversified portfolio of listed and unlisted technology investments valued at approximately $71.4 million, with unlisted assets comprising nearly 39% of the portfolio. Valuation of these Level 3 unlisted investments involves significant judgment and remains subject to market and operational uncertainties.
Looking Ahead Amid Market Uncertainty
Despite near-record global equity markets and ongoing macroeconomic uncertainties, TEK remains optimistic about long-term opportunities in technology innovation, particularly in artificial intelligence and digital infrastructure sectors. The Board emphasises patient, disciplined capital allocation as central to creating sustainable shareholder value.
With a simplified portfolio, strong investment experience, and financial flexibility, TEK is positioned to capitalise on emerging technology investments. However, the company’s ability to narrow the discount to NTA and deliver improved performance will be closely watched by investors, especially as the internal review of management effectiveness progresses.
Bottom Line?
TEK’s deepening loss and ongoing discount spotlight the challenge of translating technology investments into shareholder returns amid market volatility and valuation uncertainty.
Questions in the middle?
- How will the internal review influence TEK’s investment strategy and management structure?
- Can the share buyback program materially narrow the persistent discount to NTA?
- What impact will market volatility and valuation uncertainty have on TEK’s unlisted investments?